Back to Search
ANDREAS BEUTLER, MD
MD
Medical Oncology Physician
NPI: 1881623692Individual
Specialties, Licenses & Credentials
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
001958(NY)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
51663(MN)104152(MN)
Research & Publications (20)
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
PMID 19333944·Arthritis Rheum·2009
3-trial
The ZNF217 oncogene is a candidate organizer of repressive histone modifiers.
PMID 19242095·Epigenetics·2009
8-other
Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.
PMID 19617465·J Clin Pharmacol·2009
3-trial
Imidazol-2-and-4-ylidene by decarboxylation. Studies on the cross-conjugated mesomeric betaine-alkaloid norzooanemonine and its pseudo-cross-conjugated isomer.
PMID 18174998·Org Biomol Chem·2008
8-other
Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain.
PMID 18215993·Proc Natl Acad Sci U S A·2008
7-preclinical
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.
PMID 18975305·Arthritis Rheum·2008
3-trial
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).
PMID 18381786·J Rheumatol·2008
4-observational
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
PMID 17763439·Arthritis Rheum·2007
3-trial
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.
PMID 17665424·Arthritis Rheum·2007
3-trial
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
PMID 17114188·Ann Rheum Dis·2007
3-trial
Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis.
PMID 16960923·J Rheumatol·2006
2-rct
Comparing the incidence of anterior cruciate ligament injury in collegiate lacrosse, soccer, and basketball players: implications for anterior cruciate ligament mechanism and prevention.
PMID 16567461·Am J Sports Med·2006
8-other
Intrathecal long-term gene expression by self-complementary adeno-associated virus type 1 suitable for chronic pain studies in rats.
PMID 16445862·Mol Pain·2006
7-preclinical
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.
PMID 16439444·Ann Rheum Dis·2006
4-observational
Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis.
PMID 16096330·Ann Rheum Dis·2006
3-trial
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
PMID 15677701·Ann Rheum Dis·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 200 1ST ST SW
ROCHESTER, MN 55905 - Phone
- (507) 284-2511
Quick Facts
- NPI
- 1881623692
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 3
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile